Evidence map›Paper›PMID 40862698›Full record

ArticleAdvances in respiratory medicine2025

The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.

Aleksandra Niemiec-Górska, Olga Branicka, Paula Olszewska, Sylwia Mielcarska, Joanna Glück, Barbara Rymarczyk, Radosław Gawlik

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in respiratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aleksandra Niemiec-GórskaDepartment of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0001-8644-4048
Olga BranickaDepartment of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0002-2464-8923
Paula OlszewskaDepartment of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.
Sylwia MielcarskaDoctoral School, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0003-4228-9343
Joanna GlückDepartment of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0001-6339-9053
Barbara RymarczykDepartment of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0002-9653-0801
Radosław GawlikDepartment of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland.

Funding

Medical University of Silesia BNW-1-042/N/3/K
6 · The paper itself

Abstract

backgroundSevere asthma is associated with significant morbidity and risk of complications. Some patients, suffering from eosinophilic asthma, may benefit from biological therapies, especially anti IL-5 (anti-interleukin-5). The purpose of the study was to compare the efficacy evaluation of mepolizumab and benralizumab in the treatment of eosinophilic asthma.

methodsA retrospective, single-centre study including 59 patients with severe eosinophilic asthma treated with biologics (mepolizumab and benralizumab). Clinical outcomes, including peripheral blood morphotic characteristics, spirometry parameters, asthma control questionnaire (ACQ), mini-Asthma Quality of Life Questionnaire (mini-AQLQ) scores, daily oral corticosteroid use, body mass index, exacerbation rate, and exercise tolerance, were examined at the beginning and after 6 months of biological treatment.

resultsA total of 38 patients were treated with mepolizumab and 21 with benralizumab. Significant improvements (

conclusionsIn patients with severe eosinophilic asthma, mepolizumab and benralizumab were associated with significant improvements in clinical state. Patients with type 2 asthma will benefit from the therapy with both anti-IL5 biologic drugs.

Indexed as

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaAdultFemaleHumansMaleMiddle AgedQuality of LifeRetrospective StudiesTreatment OutcomeAnti-Asthmatic AgentsAntibodies, Monoclonal, Humanizedbenralizumabmepolizumabbenralizumabbiological treatmenteosinophilic asthmamepolizumab

Identifiers

PMID40862698
PMCPMC12382853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.